Nonsmall-cell lung cancer: Chemoprevention studies

Seminars in Thoracic and Cardiovascular Surgery

Volumn 15, Issue 4, 2003, Pages 405-420

  Karp, Daniel D ^a   Tsao, Anne S ^a   Kim, Edward S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoprevention; Lung cancer; Smoking cessation

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANETHOLE TRITHIONE; AROTINOID; BENZYL ISOTHIOCYANATE; BETA CAROTENE; BEXAROTENE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETRETINATE; FENRETINIDE; GEFITINIB; ISOTHIOCYANIC ACID DERIVATIVE; ISOTRETINOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENETHYL ISOTHIOCYANATE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; RETINAL; RETINOIC ACID DERIVATIVE; RETINOID DERIVATIVE; RETINOL; SELENIUM; SELENOMETHIONINE; TAZAROTENE; UNINDEXED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CARCINOGENICITY; CAUSE OF DEATH; CELL GROWTH; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; CLINICAL TRIAL; COMPUTER ANALYSIS; DIAGNOSTIC PROCEDURE; DIETARY INTAKE; DOSE RESPONSE; DRUG RECEPTOR BINDING; DYSPLASIA; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FEMALE; GROWTH REGULATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METAPLASIA; PASSIVE SMOKING; PRIMARY PREVENTION; RANDOMIZATION; REVIEW; SENESCENCE; SMOKING CESSATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SPUTUM CYTODIAGNOSIS; STRUCTURE ACTIVITY RELATION; THORAX RADIOGRAPHY; TOBACCO; TUMOR CELL; VITAMIN SUPPLEMENTATION; WORKPLACE;

EID: 0347766081     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/S1043-0679(03)00100-X     Document Type: Review

References (152)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. President's message to teenage smokers. Boston Herald August: 221:1, 1996
3. Strauss G, DeCamp M, Dibiccaro E, et al: Lung cancer diagnosis is being made with increasing frequency in former cigarette smokers! Proc Am Soc Clin Oncol 14: 362, 1995
4. Major Professional Organizations join Forces in light against tobacco addiction. Reuters Health Information News Service June 25, 1996
5. Garfinkel L, Stellman SD: Smoking and lung cancer in women: Findings in a prospective study. Cancer Res 48:6951-6955, 1988
6. Karp DD, Vaughan CW, Willet B, et al: Long term survival following induction chemotherapy for Squamous cell carcinoma of the head and neck: A ten year follow-up, in Salmon SE (ed): Adjuvant Therapy of Cancer V. Orlando, FL, Grune & Stratton, 1987, pp 119-128
7. Brown CC, Kessler LG: Projections of lung cancer mortality in the United States, 1985-2025. J Natl Cancer Inst 80:43-51, 1988
8. Lung cancer death rates in Boston from 1994-1996. Boston Globe November. 255:1, 1998
9. Bailar JC: Early lung cancer cooperative study group: Early lung cancer detection-Summary and conclusion. Am Rev Respir Dis 130:565(abstr), 1984
10. Mulshine JL, Tockman MS, Smart C: Considerations in the development of lung cancer screening tools. J Natl Cancer Inst 81:900-906, 1989
11. Fontant RS, Sanderson DR, Woolner LB, et al: Screening for lung cancer: A critique of the Mayo Lung Project. Cancer 67(suppl 4):1155-1164, 1991
12. Strauss GM, Gleason RE, Sugarbaker DJ: Screening for lung cancer: Another look, a different view. Chest 111: 754-768, 1997
13. Lam S, Shibuya H: Early diagnosis of lung cancer. Clin Chest Med 354:99-105, 1999
14. Flehinger BH, Melamed MR, Zaman MB, et al: Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Memorial-Sloan Kettering study. Am Rev Respir Dis 130:555-560, 1984
15. Fontana RS, Sanderson DR, Woolner LB, et al: Lung cancer screening: The Mayo program. J Occup Med 28:746-750, 1986
16. Frost JK, Ball WC, Levin ML: Early lung cancer detection: Results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 13:549-554, 1984
17. Saito Y, Takahashi S, Usada K, et al: Detection of early cancer by lung cancer screening. Nippon Rinsho 54: 1410-1414, 1996
18. Tockman MS, Mulshine JL, Piantadosi S, et al: Prospective detection of preclinical lung cancer: Results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 over-expression. Clin Cancer Res 3:2237-2246, 1997
19. Zhou J, Mulshine JL, Unsworth EJ, et al: Purification and characterization of a protein that permits early detection of lung cancer: Identification of a heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J Biol Chem 271:10760-10766, 1996
20. Tockman MS, Gupta PK, Myers JD, et al: Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: A new approach to early lung cancer defection. J Clin Oncol 6:1685-1693, 1988
21. Fielding P, Turnbull L, Prime W, et al: Heterogeneous nuclear ribonucleoprotein A2/B1 upregulation in bronchial lavage specimens: A clinical marker of early lung cancer detection. Clin Cancer Res 5:4048-4052, 1999
22. Sundaresan V, Ganly P, Haselton P, et al: p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in pre-invasive lesions of the bronchus. Oncogene 7:1989-1997, 1992
23. Kishimoto Y, Sugio K, Hung JY: Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small lung cancers. J Natl Cancer Inst 87:1224-1229, 1995
24. Mao L, Lee DJ, Tockman MS, et al: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A 91:9871-9875, 1994
25. Wistuba II, Behrens C, Milchgrub S: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18:643-650, 1999
26. Mao L, Lee JS, Kurie JM: Clorial genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89:857-862, 1997
27. Mulshine JL, DeLuca LM, Dedrick RL: Regional delivery of retinoids, in Martinet Y, Martinet N, Vignaud JM, et al (eds): Clinical and Biological Basis of Lung Cancer Prevention. Basal, Switzerland, Birkhauser, 1998, pp 273-284
28. Payne PW, Sebo TJ, Doudkine A, et al: Sputum screening by quantitative microscopy: Reexamination of a portion of the National Cancer Institute cooperative early lung cancer study. Mayo Clin Proc 72:697-704, 1997
29. Lam S, Kennedy T, Unger M, et al: Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 113:696-702, 1998
30. Udaya B, Prakash S: Advances in bronchoscopic procedures. Chest 116:1403-1408, 1999
31. Henschke CI, McCauley DI, Yankelevitz, et al: Early Lung Cancer Action Project: Overall design and findings from baseline screening. Lancet 354:99-105, 1999
32. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
33. Slaughter DP: The multiplicity of origin of malignant tumors: Collective review. Internat Abstr Surg 79:89-98, 1944
34. Slaughter DP: Multicentric origin of intraoral carcinoma. Surgery 20:133-146, 1946
35. Slaughter DP, Southwick HW, Smejkal W: "Field cancerization" in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer 6:963-968, 1953
36. Auerbach O, Patrick TG, Stout AP, et al: The anatomical approach to the study of smoking and bronchogenic carcinoma: A preliminary report of forty-one cases. Cancer 9:76-83, 1956
37. Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332-1338, 1976
38. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal tumor development. N Engl J Med. 319:525-535, 1988
39. Huber MH, Lee JS, Hong WK: Chemoprevention of lung cancer. Semin Oncol 20:128-141, 1993
40. Westra WH, Slebos RJ, Offerhaus GJ, et al: K-ras oncegene activation in lung adenocarcinomas from former smokers: Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72:432-438, 1993
41. Johnson BE: The role of MYC, JUN, and FOS Oncogenes, in Pass HI, Mitchell JB, Johnson DH, et al (eds): Human Lung Cancer. Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, pp 83-98
42. Morkve O, Halvorsen OJ, Stangeland L, et al: Quantitation of biological markers (p53, c-myc, Ki-67, and DNA ploidy) by multiparameter flow cytometry in non-small cell lung cancer. Int J Cancer 52:851-855, 1992
43. Vogt PK, Bos TJ: Jun: Oncogenes and transcription factors. Adv Cancer Res 55:1-35, 1990
44. Angel P, Karin M: The role of Jun, Fos, and the AP-1 complex in cell proliferation and transformation. Biochem Biophys Arta 1072:129-157, 1991
45. Distel RJ, Spiegelman BM: Protooncogene c-fos as a transcription factor. Adv Cancer Res 55:37-55, 1990
46. Hong WK, Lippman SM, Hittelman WN, et al: Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic. Clin Cancer Res 1:677-686, 1995
47. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene,: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994
48. Gibbs JB, Oliff A Kohl NE: Farnesyltransferase inhibitors: ras rescarch yields a potential cancer therapeutic. Cell 77:175-178, 1994
49. Islam SS, Schottenfeld D: Declining FEV1 and chronic productive cough in cigarette smokers: A 25-year prospective study of lung cancer incidence in Tecumseh, Michigan. Cancer Epidemiol Biomarkers Prev 3:289-298, 1994
50. Schottenfeld D: Epidemiology of lung cancer, in Pass HI, Mitchell JB, Johnson DH, et al (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott-Raven Publishers, 1996, pp 305-321
51. Knudson AG: Hereditary cancer, oncogenes, and anti-oncogenes. Cancer Res 45:1437-1443, 1985
52. Mattson ME, Pollack ES, Cullen JW: What are the odds that smoking will kill you? Am J Public Health 77:425-431, 1987
53. Krontiris TG, Devlin B, Karp DD, et al: An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 329:517-523, 1993
54. Speirs CJ, Murray S, Davies DS, et al: Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol. 29:101-109, 1990
55. Shaw GL, Falk RT, Frame JN, et al: Genetic polymorphism of CYP2D6 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 7:215-219, 1998
56. Kivisto KT, Griese EU, Stuven T, et al: Analysis of CYP2D6 expression in human lung: Implications for the association between CYP2D6 activity and susceptibility to lung cancer. Pharmacogenetics 7:295-302, 1997
57. Raunio H, Husgafvel-Pursiainen K, Anttila S, et al: Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-A review. Gene 159:113-121, 1995
58. Hirvonen A: Genetic factors in individual responses to environmental exposures. Occup Environ Med 37:37-43, 1995
59. Sporn MB: Carcinogenesis and cancer-Different perspectives on the same disease. Cancer Res 51:6215-6218, 1991
60. Willett WM, MacMahon B: Diet and cancer: An overview. N Engl J Med 310:697-703, 1984
61. Smith MA, Parkinson DR, Cheson BD, et al: Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992
62. Borden EC, Lotan R, Levens D, et al: Differentiation therapy of cancer: Laboratory and clinical investigations (Meeting Report). Cancer Res 53:4109-4115, 1993
63. Gudas L, Hu L: The regulation and gene expression by retinoids in normal and tumorigenic epithelial cells. Proc Annu Meet Am Assoc Cancer Res 34:588-589, 1993
64. Kitamura M, Shirasawa T, Mitarai T, et al: A retinoid responsive cytokine gene, MK is preferentially expressed in the proximal tubules of the kidney and human tumor cell lines. Am J Pathol 142:425-431, 1993
65. Wagner H, Ruckdeschel JC: Screening, early detection, and early intervention strategies for lung cancer. Cancer Control. J Moffitt Cancer Center 6:493-502, 1995
66. Gebert JF, Moghal N, Frangioni JV, et al: High frequency of retinoic acid receptor beta abnormalities in human lung cancer. Oncogene 6:1859-1868, 1991
67. Lotan R, Sozzi G, Ro J, et al: Selective suppression of retinoic acid receptor b (RAR-b) expression in squamous metaplasia and in non-small cell lung cancers (NSCLC) compared to normal bronchial epithelium. Proc Am Soc Clin Oncol 14:165, 1995
68. Lotan R, Xu XC, Lippman SM, et al: Suppression of retinoic acid receptor in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332:1405-1410, 1995
69. Lippman SM, Heyman RA, Kurie JM, et al: Retinoids and chemoprevention: Clinical and basic studies. J Cell Biochem Suppl 22:1-10, 1995
70. Kurie JM: Personal communication, 2002
71. Kohlhaufl M, Haussinger K, Stanzel F, et al: Inhalation of aerosolized vitamin A: Reversibility of metaplasia and dysplasia of human respiratory epithelia - A prospective pilot study. Eur J Med Res 7:72-78, 2002
72. van Zandwijk N: N-Acetylcysteine (NAC) and glutathione (GSH): Antioxidant and chemopreventive properties, with special reference to lung cancer. J Cell Biochem Suppl 22:24-32, 1995
73. Cochrane CG: Cellular injury by oxidants. Am J Med 91:23-30, 1991
74. Webb WR: Clinical evaluation of a new mucolytic agent acetyl cysteine. J Thorac Cardiovasc Surg 44:330-343, 1962
75. Meister A, Anderson M: Glutathione. Ann Rev Biochem 52:711-760, 1983
76. Miller LF, Rumack BH: Clinical safety of high oral doses of acetylcysteine. Semin Oncol 10(suppl 1):76-85, 1983
77. De Flora S, Cesarone CF, Balansky RM, et al: Chemopreventive properties and mechanisms of N-Acetylcysteine. The Experimental Background. J Cell Biochem Suppl 22:33-41, 1995
78. Conaway CC, Jiao D, Kelloff GJ, et al: Chemopreventive potential of fumaric acid, N-acetylcysteine, N-(4-hydroxyphenyl) retinamide and á-carotene for tobacco-nitrosamine induced lung tumors in A/J mice. Cancer Lett 124:85-93, 1998
79. van Zandwijk N, Pastorino U, de Vries N, et al: EUROSCAN: The European organization for research and treatment of cancer (EORTC): Chemoprevention study in lung cancer. Lung Cancer 9:351-356, 1993
80. Menkes MS, Constock GW, Vuilleumier JP, et al: Serum beta carotene, vitamin A and E, and selenium and the risk of lung cancer. N Engl J Med 315:1250-1254, 1986
81. Dimery I, Shirinian M, Heyne K, et al: Reduction in toxicity of high-dose 13-cis-retinoic acid (13-cRA) with a tocopherol (AT). Proc Am Soc Clin Oncol 11:399, 1992
82. Shin DM, Mao L, Papadimitrakopoulou V, et al: Modulation of biomarkers with biochemoprevention therapy in advanced premalignant lesions in the upper aerodigestive tract. Proc Annu Meet Soc Clin Oncol 16:A1557, 1997
83. Shamberger RJ, Frost DV: Possible protective effect of selenium against human cancer. Can Med Assoc J 100: 682, 1969
84. van den Brandt PA, Goldbohm RA, van't Veer P, et al: A prospective cohort study on selenium status and the risk of lung cancer. Cancer Res 53:4860-4865, 1993
85. Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957-1963, 1996
86. Blot WJ, Li JY, Taylor PR, et al: Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85:1483-1492, 1993
87. Hecht SS: Chemoprevention of lung cancer by isothiocyanates. Adv Exp Med Biol 401:1-11, 1996
88. Kensler TW, Egner PA, Dolan PM, et al: Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1, 2-dithiol-3-thione (oltipraz) and related 1, 2-dithiol-3-thiones and 1, 2-dithiol-3-ones. Cancer Res 47:4271-4277, 1987
89. Reddy BS, Rao CV, Rivenson A, et al: Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res 53:3493-3498, 1993
90. Rusch V, Klimstra D, Venkatraman E, et al: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor a is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 2:515-522, 1997
91. Kurie JM, Shin H, Lee J, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 2:1787-1793, 1996
92. Dittadi R, Gion M, Pagan V, et al: Epidermal growth factor receptor in lung malignancies: Comparison between cancer and normal tissue. Br J Cancer 64:741-744, 1991
93. Fujino S, Enokibori T, Tezuka N, et al: A comparison of epidermal growth factor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 32:2070-2074, 1996
94. Rusch V, Klimstra DS, Linkov I, et al: Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and co-expression precedes squamous cell carcinoma development. Cancer Res 55:1365-1372, 1995
95. Salomon D, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
96. Fernandes A, Hamburger A, Gerwin B: Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Am J Respir Cell Mol Biol 21:701-709, 1999
97. Rusch V, Mendelsohn J, Dmitrovsky E: The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev 7:133-141, 1996
98. Podsypanina K, Ellenson LH, Nemes A, et al: Mutation of Pten/MMAC1 in mice causes neoplasia in multiple organs. Proc Natl Acad Sci U S A 96:1563-1568, 1999
99. Bellacosa A, Testa JR, Staal SP, et al: A retroviral oncegene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254:274-277, 1991
100. Hutchinson J, Jin J, Cardiff RD, et al: Activation of AKT (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 21:2203-2212, 2001
101. DiCristofano A, Pesce B, Cordon-Cardo C, et al: PTEN is essential for embryonic development and tumor suppression. Nat Genet 19:348-355, 1998
102. Chang HW, Aoki M, Fruman D, et al: Transformation of chicken cells by the gene encoding the catalytic subunit of PI3-kinase. Science 276:1848-1850, 1997
103. AstraZeneca: ZD1839 Investigator's Brochure. Waltham, MA, AstraZeneca Pharmaceuticals LP, 2001
104. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848, 1997
105. Modjtahedi H, Styles JM, Dean CJ: The human EGF receptor as a target for cancer therapy: Six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 67:247-253, 1993
106. Modjtahedi H, Eccles S, Box G, et al: Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67:254-261, 1993
107. Modjtahedi H, Eccles SA, Box G, et al: Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell Biophys 22:129-146, 1993
108. Easty DM, Easty GC, Carter RL, et al: Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer 43:772-785, 1981
109. Genentech, Inc: Investigator's Brochure: OSI-774. San Francisco, CA, Genentech, Inc, 2001
110. Wolff H, Saukkonen K, Anttila S, et al: Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997-5001, 1998
111. Hida T, Yatabe Y, Achiwa H, et al: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58:3761-3764, 1998
112. Achiwa H, Yatabe Y, Hida T, et al: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 5:1001-1005, 1999
113. Khuri FR, Wu H, Lee JJ, et al: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7:861-867, 2001
114. Rowlinson SW, Crews BC, Goodwin DC, et al: Spatial requirements for 15-R-hydroxy-5Z, 8Z, 11Z, 13E-eicosatetraenoic acid synthesis within the cyclooxygenase active site of murine COX-2. Why acetylated COX-1 does not synthesize 15-R-HETE. J Biol Chem 275:6586-6591, 2000
115. Giardiello FM, Hamilton SR, Krush AJ, et al: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993
116. Giovannucci E, Egan KM, Hunter DJ, et al: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614, 1995
117. Steinbach G, Lunch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000
118. Thun MJ, Namboodiri MM, Heath CW: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991
119. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138-146, 1994
120. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al: Aspirin and lung cancer in women. Br J Cancer 87:49-53, 2002
121. Harris RE, Beebe-Donk J, Schuller HM: Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 9:693-695, 2002
122. Estenser RD, Wattenberg LW: Studies of the chemopreventive effects of myo-inositol on benzo[a]pyrene induced neoplasia of the lung and forestomach of female A/J mice. Carcinogenesis 14:1975-1977, 1993
123. Wattenberg L: Chalcones, myo-Inositol and other novel inhibitors of pulmonary carcinogenesis. J Cell Biochem Suppl 22:162-168, 1995
124. Wattenberg LW, Wiedmann TS, Estensen RD, et al: Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 57: 5489-5492, 1997
125. Nelson JF, Karelus K, Bergman MD, et al: Neuroendocrine involvement in aging: Evidence from studies of reproductive aging and caloric restriction. Neurobiol Aging 16:837-843, 1995
126. Weindruch R: Dietary restriction, tumors, and aging in rodents. J Gerontol 44:67-71, 1989
127. Yang G, Wang ZY, Kim S, et al: Characterization of early pulmonary hyperproliferation and tumor progression and their inhibition by black tea in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model with A/J mice. Cancer Res 57:1889-1894, 1997
128. Suganuma M, Okabe S, Sueoka N, et al: Green tea and cancer chemoprevention. Mutat Res 428:339-344, 1996
129. Marquez C, Treston A, You L, et al: Chemoprevention of lung adenomas by BW2258U89. Proc Am Assoc Cancer Res 7:270, 1996
130. Moody T, You L, Jakowlew S, et al: Chemoprevention of lung adenomas by a VIP receptor antagonist. Proc Am Assoc Cancer Res 7:364, 1996
131. Huber MH, Lippman SM: Chemoprevention strategies, in Pass HI, Mitchell JB, Johnson DH, et al (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott-Raven Publishers, 1996, pp 351-358
132. Hennekans CH, Buring JE, Manson JE, et al: Lack of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334:1145-1149, 1996
133. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994
134. McLarty JW, Holiday DB, Girard WM, et al: Beta-carotene, vitamin A, and lung cancer chemoprevention: Results of an intermediate endpoint study. Am J Clin Nutr 62(suppl 6):1431S-1438S, 1995
135. Arnold AM, Browman GP, Levine MN, et al: The effect of the synthetic retinoid etretinate on sputum cytology: Results from a randomized trial. Br J Cancer 65:737-743, 1992
136. Lee JS, Lippman SM, Benner SE, et al: Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 12:937-945, 1994
137. Kurie JM, Lee JS, Khuri FR, et al: N-(4-hydroxyphenyl)-retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6:2973-2979, 2000
138. Soria JC, Moon C, Wang L, et al: Effects of N-(4-hydroxyphenyl) retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 93:1257-1263, 2001
139. Lam S, MacAulay C, le Riche J, et al: A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer lost 93: 1001-1009, 2002
140. Lippman SM, Lee JJ, Karp DD, et al: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 93:605-618, 2001
141. Pastorino U, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222, 1993
142. Van Zandwijk N, Dalesio O, Pasotino U, et al: EUROSCAN, a randomized trial of vitamin A and N-acetyleysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92:977-986, 2000
143. Misset JL, Mathe G, Santelli G, et al: Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment. Cancer Detect Prev 9:167-170, 1986
144. Thomas P, Rubinstein L, the Lung Cancer StudyGroup: Cancer recurrence after resection: T1N0 non-small cell lung cancer. Ann Thorac Surg 49:242-246, 1990
145. Current Clinical Trials: Oncology. Natl Cancer Inst 3:199, 1996
146. Beahrs OH, Henson DE, Hutter RVP, et al: Handbook for Staging of Cancer. American Joint Committee on Cancer. Philadelphia, PApp 129-136: Lippincott; 1993
147. Travis WD, Linder J, Machay B: Classification, histology, cytology, and electron microscopy, in Pass HI, Mitchell JB, Johnson DH, et al (eds): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, pp 361-395
148. Melamed MR, Zaman MB, Flehinger BH, et al: Radiologically occult in situ and incipient invasive epidermoid lung cancer: Detection by sputum cytology in a survey of asymptomatic cigarette smokers. Am J Surg Pathol 1:5-16, 1977
149. Frost JK, Ball WC Jr, Levin ML, et al: Sputum cytopathology: Use and potential in monitoring the workplace environment by screening for biological effects of explosure. J Occup Med 28:692-703, 1986
150. Cameron R, Fringer J, Taylor C, et al: Practice guidelines for non-small cell lung cancer. Cancer J Sci Am 2(suppl 3A):S69-S77, 1996
151. Edell ES, Cortese DA: Photodynamic therapy. Its use in the management of bronchogenic carcinoma. Clin Chest Med 16:455-463, 1995
152. Frontiers in Cancer Prevention Research The American Association for Cancer Research. Boston, MA, October 14-18, 2002